Download PDF

1. Company Snapshot

1.a. Company Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.It is also developing OPN-019 that combines liquid EDS device with an antiseptic.


The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation.OptiNose, Inc.was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Show Full description

1.b. Last Insights on OPTN

OptiNose's recent performance was driven by a $330 million acquisition deal with Paratek Pharmaceuticals, which represents a 50% premium to its closing trading price on March 19, 2025. This strategic partnership is expected to accelerate access for XHANCE beyond specialists to primary care providers, maximizing the recent label expansion for Chronic Rhinosinusitis (CRS) in a ~10-million-patient market. The acquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies. Additionally, the company's Q4 loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70 is a positive indicator, as it beats expectations.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

May -15

Source: zacks.com

Card image cap

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

Mar -26

Source: zacks.com

Card image cap

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

Mar -24

Source: zacks.com

Card image cap

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

Mar -21

Source: businesswire.com

Card image cap

OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

Mar -21

Source: zacks.com

Card image cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

Mar -21

Source: globenewswire.com

Card image cap

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Beacon Roofing Supply, Inc. - BECN

Mar -20

Source: prnewswire.com

Card image cap

Optinose just downgraded at Piper Sandler, here's why

Mar -20

Source: https://thefly.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.90%)

6. Segments

Products fo Patients Treated by Ear, Nose and Throat and Allergy Specialists

Expected Growth: 8.9%

Strong demand for OptiNose's products, particularly XHANCE, driven by increasing prevalence of chronic sinusitis and nasal polyps, coupled with growing adoption of nasal spray treatments among Ear, Nose and Throat (ENT) and Allergy specialists, contributes to the 8.9% growth rate.

7. Detailed Products

Xhance

A prescription nasal spray used to treat nasal polyps in adults

Onzetra Xsail

A prescription nasal spray used to treat acute migraines in adults

Avspire

A prescription nasal spray used to treat allergic rhinitis

8. OptiNose, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

OptiNose, Inc. has a moderate threat of substitutes due to the presence of alternative treatments for nasal polyps and chronic sinusitis. However, the company's proprietary OptiNose Exhalation Delivery System (EDS) technology provides a unique and effective treatment option, reducing the threat of substitutes.

Bargaining Power Of Customers

OptiNose, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options for nasal polyps and chronic sinusitis. This gives the company significant pricing power and negotiating leverage with customers.

Bargaining Power Of Suppliers

OptiNose, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for its raw materials and manufacturing services. However, the company's reliance on a few key suppliers for certain components increases its bargaining power.

Threat Of New Entrants

OptiNose, Inc. faces a high threat of new entrants due to the growing demand for innovative treatments for nasal polyps and chronic sinusitis. New entrants could potentially disrupt the market and challenge OptiNose's market share.

Intensity Of Rivalry

OptiNose, Inc. operates in a moderately competitive market with a few established players. The company's unique technology and product offerings provide a competitive advantage, but the market is still subject to intense competition and pricing pressure.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 291.85%
Debt Cost 3.95%
Equity Weight -191.85%
Equity Cost 3.44%
WACC 4.92%
Leverage -152.12%

11. Quality Control: OptiNose, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
ANI Pharmaceuticals

A-Score: 5.0/10

Value: 4.3

Growth: 6.0

Quality: 4.4

Yield: 0.0

Momentum: 9.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Phibro Animal Health

A-Score: 4.9/10

Value: 2.7

Growth: 5.2

Quality: 4.2

Yield: 4.0

Momentum: 9.5

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
OptiNose

A-Score: 4.4/10

Value: 7.4

Growth: 4.4

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Aquestive Therapeutics

A-Score: 4.4/10

Value: 8.0

Growth: 3.7

Quality: 5.8

Yield: 0.0

Momentum: 7.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Evolus

A-Score: 4.1/10

Value: 9.2

Growth: 7.2

Quality: 6.2

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
SCYNEXIS

A-Score: 3.2/10

Value: 7.8

Growth: 5.4

Quality: 4.6

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.6$

Current Price

9.6$

Potential

-0.00%

Expected Cash-Flows